Zobrazeno 81 - 90
of 245
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Egbert F. Smit, Rieneke van de Ven, Adrianus J. de Langen, Christian G. Slockers, Johannes M.A. Daniels, Sayed M.S. Hashemi, Tanja D. de Gruijl, Erik Thunnissen, Anita G.M. Stam, Anna Larissa N. Niemeijer
Publikováno v:
van de Ven, R, Niemeijer, A-L N, Stam, A G M, Hashemi, S M S, Slockers, C G, Daniels, J M, Thunnissen, E, Smit, E F, de Gruijl, T D & de Langen, A J 2017, ' High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes ', ERS Monograph, vol. 3, no. 2, 00110-2016 . https://doi.org/10.1183/23120541.00110-2016, https://doi.org/10.1183/23120541.00110-2016
ERJ Open Research, Vol 3, Iss 2 (2017)
ERS Monograph, 3(2):00110-2016. European Respiratory Society
Van de Ven, R, Niemeijer, A-L N, Stam, A G, Hashemi, S M, Slockers, C G, Daniels, J M, Thunnissen, E, Smit, E F, de Gruijl, T D & de langen, A J 2017, ' High PD-1 expression on regulatory and effector T cells in lung cancer draining lymph nodes ', Cancer Research, vol. 77 . https://doi.org/10.1158/1538-7445.AM2017-4584
Cancer Research, 77. American Association for Cancer Research Inc.
ERJ Open Research
ERJ Open Research, Vol 3, Iss 2 (2017)
ERS Monograph, 3(2):00110-2016. European Respiratory Society
Van de Ven, R, Niemeijer, A-L N, Stam, A G, Hashemi, S M, Slockers, C G, Daniels, J M, Thunnissen, E, Smit, E F, de Gruijl, T D & de langen, A J 2017, ' High PD-1 expression on regulatory and effector T cells in lung cancer draining lymph nodes ', Cancer Research, vol. 77 . https://doi.org/10.1158/1538-7445.AM2017-4584
Cancer Research, 77. American Association for Cancer Research Inc.
ERJ Open Research
The treatment of advanced nonsmall cell lung cancer (NSCLC) with PD-1/PD-L1 immune checkpoint inhibitors has improved clinical outcome for a proportion of patients. The current challenge is to find better biomarkers than PD-L1 immunohistochemistry (I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d11b8dbe0528d3e5b8389a10f0292f7
https://research.vumc.nl/en/publications/500525e5-47b1-48dd-aeca-f7bbbea72e3b
https://research.vumc.nl/en/publications/500525e5-47b1-48dd-aeca-f7bbbea72e3b
Autor:
Fenna Bohme, John P. Veluchamy, Tanja D. de Gruijl, Hans van Vliet, Jan Spanholtz, María Delso-Vallejo, Nina Kok, Volker Huppert, Ruth Seggewiss-Bernhardt
Publikováno v:
Scientific Reports, 7:43873. Nature Publishing Group
Veluchamy, J P, Delso-Vallejo, M, Kok, N, Bohme, F, Seggewiss-Bernhardt, R, Van Der Vliet, H J, De Gruijl, T D, Huppert, V & Spanholtz, J 2017, ' Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function ', Scientific Reports, vol. 7, 43873 . https://doi.org/10.1038/srep43873
Scientific Reports
Veluchamy, J P, Delso-Vallejo, M, Kok, N, Bohme, F, Seggewiss-Bernhardt, R, Van Der Vliet, H J, De Gruijl, T D, Huppert, V & Spanholtz, J 2017, ' Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function ', Scientific Reports, vol. 7, 43873 . https://doi.org/10.1038/srep43873
Scientific Reports
Advancements in multi-colour fluorescence activated cell sorting (FACS) panel warrant harmonized procedures to obtain comparable data between various laboratories. The intensifying clinical exploration of Natural Killer (NK) cell-based immunotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63120cd0d6125521f69e77e4e3331038
https://research.vumc.nl/en/publications/f8de79a6-0ed1-4ac4-9bfa-34c7e6e79b14
https://research.vumc.nl/en/publications/f8de79a6-0ed1-4ac4-9bfa-34c7e6e79b14
Autor:
Hans J. van der Vliet, Tanja D. de Gruijl, Fenna Bohme, Henk M.W. Verheul, Jan Spanholtz, James P. Di Santo, Daniëlle A.M. Heideman, Nina Kok, Silvia Lopez-Lastra, John P. Veluchamy
Publikováno v:
Veluchamy, J P, Lopez-Lastra, S, Spanholtz, J, Bohme, F, Kok, N, Heideman, D A M, Verheul, H M W, Di Santo, J P, de Gruijl, T D & van der Vliet, H J 2017, ' In Vivo efficacy of umbilical cord blood stem cell-derived NK cells in the treatment of metastatic colorectal cancer ', Frontiers in Immunology, vol. 8, no. FEB, 87 . https://doi.org/10.3389/fimmu.2017.00087
Frontiers in Immunology
Frontiers in Immunology, 8(FEB):87. Frontiers Media S.A.
Frontiers in Immunology
Frontiers in Immunology, 8(FEB):87. Frontiers Media S.A.
Therapeutic monoclonal antibodies against the epidermal growth factor receptor (EGFR) act by inhibiting EGFR downstream signaling and by eliciting a natural killer (NK) cell-mediated antitumor response. The IgG1 mAb cetuximab has been used for treatm
Autor:
Anne-Marie Cleton-Jansen, Vincenzo Canzonieri, Monique A. J. van Eijndhoven, Laura Roncuzzi, Sulev Kõks, Tonny Lagerweij, Nicoletta Zini, Massimo Dominici, Maria Pérez-Lanzón, Roberta Bonafede, Tanja D. de Gruijl, Silvia Cervo, Aare Märtson, Nicolas Léveillé, D. Michiel Pegtel, Nicola Baldini, Thomas Wurdinger, Xuan Dung Ho, Agostino Steffan, Katre Maasalu, Ekaterina S. Jordanova, S. Rubina Baglio, Giulia Grisendi, M. Greco, Sonia A. Melo, Sinéad M. Lougheed
Publikováno v:
Clinical Cancer Research, 23(14), 3721-3733. American Association for Cancer Research Inc.
Clinical cancer research, 23(14), 3721-3733. American Association for Cancer Research Inc.
Clinical Cancer Research, 23(14), 3721-3733
Baglio, S R, Lagerweij, T, Pérez-Lanzón, M, Ho, X D, Léveillé, N, Melo, S A, Cleton-Jansen, A M, Jordanova, E S, Roncuzzi, L, Greco, M, Van Eijndhoven, M A J, Grisendi, G, Dominici, M, Bonafede, R, Lougheed, S M, De Gruijl, T D, Zini, N, Cervo, S, Steffan, A, Canzonieri, V, Martson, A, Maasalu, K, Köks, S, Wurdinger, T, Baldini, N & Pegtel, D M 2017, ' Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression ', Clinical Cancer Research, vol. 23, no. 14, pp. 3721-3733 . https://doi.org/10.1158/1078-0432.CCR-16-2726
Clinical cancer research, 23(14), 3721-3733. American Association for Cancer Research Inc.
Clinical Cancer Research, 23(14), 3721-3733
Baglio, S R, Lagerweij, T, Pérez-Lanzón, M, Ho, X D, Léveillé, N, Melo, S A, Cleton-Jansen, A M, Jordanova, E S, Roncuzzi, L, Greco, M, Van Eijndhoven, M A J, Grisendi, G, Dominici, M, Bonafede, R, Lougheed, S M, De Gruijl, T D, Zini, N, Cervo, S, Steffan, A, Canzonieri, V, Martson, A, Maasalu, K, Köks, S, Wurdinger, T, Baldini, N & Pegtel, D M 2017, ' Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression ', Clinical Cancer Research, vol. 23, no. 14, pp. 3721-3733 . https://doi.org/10.1158/1078-0432.CCR-16-2726
Purpose: Human osteosarcoma is a genetically heterogeneous bone malignancy with poor prognosis despite the employment of aggressive chemotherapy regimens. Because druggable driver mutations have not been established, dissecting the interactions betwe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6fc995d21f815df8513d6bb494316e5
https://hdl.handle.net/11368/2967826
https://hdl.handle.net/11368/2967826
Autor:
Dung T. Le, Shintaro Iwama, Winald R. Gerritsen, Tanja D. de Gruijl, Schey Cherng Tzou, Patrizio Caturegli, Saskia J. A. M. Santegoets, Alfons J.M. van den Eertwegh, Lei Zheng, Todd D. Armstrong, Daniel A. Laheru, Monica V. Talor, Elizabeth M. Jaffee, Alessandra De Remigis, Susan F. Slovin, Jennifer N. Uram
Publikováno v:
International Journal of Cancer. 136:127-137
Cancer immunotherapy induces a variety of autoinflammatory responses, including those against the thyroid gland, which can be exploited to predict clinical outcomes. Considering the paucity of information about thyroid autoimmunity in patients receiv
Autor:
Claudia C. Sombroek, Rieneke van de Ven, Rik J. Scheper, Tanja D. de Gruijl, Jelle J. Lindenberg, Dinja Oosterhoff, Anita G.M. Stam, Alfons J.M. van den Eertwegh, Hans J. P. M. Koenen, Sinéad M. Lougheed
Publikováno v:
Human Vaccines & Immunotherapeutics, 10(6), 1622-1632. Landes Bioscience
Lindenberg, J J, van de Ven, R, Oosterhoff, D, Sombroek, C C, Lougheed, S M, Stam, A G M, Koenen, H J P M, van den Eertwegh, A J M, Scheper, R J & de Gruijl, T D 2014, ' Induction of dendritic cell maturation in the skin microenvironment by soluble factors derived from colon carcinoma ', Human Vaccines & Immunotherapeutics, vol. 10, no. 6, pp. 1622-1632 . https://doi.org/10.4161/hv.28548
Human Vaccines & Immunotherapeutics, 10, 6, pp. 1622-32
Human Vaccines & Immunotherapeutics, 10, 1622-32
Lindenberg, J J, van de Ven, R, Oosterhoff, D, Sombroek, C C, Lougheed, S M, Stam, A G M, Koenen, H J P M, van den Eertwegh, A J M, Scheper, R J & de Gruijl, T D 2014, ' Induction of dendritic cell maturation in the skin microenvironment by soluble factors derived from colon carcinoma ', Human Vaccines & Immunotherapeutics, vol. 10, no. 6, pp. 1622-1632 . https://doi.org/10.4161/hv.28548
Human Vaccines & Immunotherapeutics, 10, 6, pp. 1622-32
Human Vaccines & Immunotherapeutics, 10, 1622-32
Autologous tumor cell-based vaccines provide a wide range of tumor antigens and personalized neo-epitopes based on individual tumors’ unique antigenic mutanome signatures. However, tumor-derived factors may hamper in situ maturation of dendritic ce
Autor:
Nico J. Meeuwenoord, Gijsbert A. van der Marel, Renske Goedemans, Dmitri V. Filippov, Rob Valentijn, Nikki M. Loof, Marij J. P. Welters, Sinéad M. Lougheed, Gijs G. Zom, Sjoerd H. van der Burg, Ferry Ossendorp, Cornelis J. M. Melief, Tanja D. de Gruijl, Maarten L. Zandvliet
Publikováno v:
Zom, G G, Welters, M J P, Loof, N M, Goedemans, R, Lougheed, S, Valentijn, R R P M, Zandvliet, M L, Meeuwenoord, N J, Melief, C J M, de Gruijl, T D, Van der Marel, G A, Filippov, D V, Ossendorp, F & Van der Burg, S H 2016, ' TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients ', Oncotarget, vol. 7, no. 41, pp. 67087-67100 . https://doi.org/10.18632/oncotarget.11512
Oncotarget, 7(41), 67087-67100
Oncotarget, 7(41), 67087-67100. Impact Journals
Oncotarget
Oncotarget, 7(41), 67087-67100
Oncotarget, 7(41), 67087-67100. Impact Journals
Oncotarget
// Gijs G. Zom 1 , Marij J.P. Welters 2 , Nikki M. Loof 2 , Renske Goedemans 2 , Sinead Lougheed 3 , Rob R.P.M. Valentijn 4 , Maarten L. Zandvliet 4 , Nico J. Meeuwenoord 5 , Cornelis J.M. Melief 1, 6 , Tanja D. de Gruijl 3 , Gijsbert A. Van der Mare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d3a5974f24afaca24b673755643dda6
https://research.vumc.nl/en/publications/2e1e29d1-1ac9-42aa-8538-377839a57f57
https://research.vumc.nl/en/publications/2e1e29d1-1ac9-42aa-8538-377839a57f57
Autor:
Arjan W. Griffioen, Hans J. van der Vliet, Epie Boven, Siu W. Lam, Maudy Walraven, Henk M.W. Verheul, Henk J. Broxterman, Roberto Pili, Tanja D. de Gruijl, Madelon Q. Wentink
Publikováno v:
British Journal of Cancer, 115(8), 940-948. Nature Publishing Group
British Journal of Cancer
Wentink, M Q, Broxterman, H J, Lam, S W, Boven, E, Walraven, M, Griffioen, A W, Pili, R, van der Vliet, H J, de Gruijl, T D & Verheul, H M W 2016, ' A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer ', British Journal of Cancer, vol. 115, no. 8, pp. 940-948 . https://doi.org/10.1038/bjc.2016.275
British Journal of Cancer
Wentink, M Q, Broxterman, H J, Lam, S W, Boven, E, Walraven, M, Griffioen, A W, Pili, R, van der Vliet, H J, de Gruijl, T D & Verheul, H M W 2016, ' A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer ', British Journal of Cancer, vol. 115, no. 8, pp. 940-948 . https://doi.org/10.1038/bjc.2016.275
Background: Only a small proportion of patients respond to anti-VEGF therapy, pressing the need for a reliable biomarker that can identify patients who will benefit. We studied the biological activity of anti-VEGF antibodies in patients' blood during
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba870abc5bfac84b453e8c971a0c6045
https://research.vumc.nl/en/publications/efd68579-8148-4960-9dc3-79816f0c4326
https://research.vumc.nl/en/publications/efd68579-8148-4960-9dc3-79816f0c4326
Autor:
Martijn R. Meijerink, Foke van Delft, Cornelis van Kuijk, Jantien A. Vogel, Jill Witvliet, Marcus C. de Jong, Babs M Zonderhuis, Hester J. Scheffer, Tanja D. de Gruijl, Anita G.M. Stam, Marian A. E. de van der Schueren, Petrousjka van den Tol, Geert Kazemier, Marc G. Besselink, Freek Daams, Laurien G. P. H. Vroomen, Marleen C. A. M. Melenhorst
Publikováno v:
Scheffer, H J, Vroomen, L G P H, de Jong, M C, Melenhorst, M C A M, Zonderhuis, B M, Daams, F, Vogel, J A, Besselink, M G H, van Kuijk, C, Witvliet, J, de van der Schueren, M A E, de Gruijl, T D, Stam, A G M, van den Tol, P M P, van Delft, F, Kazemier, G & Meijerink, M R 2016, ' Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation : Results of the Phase I/II PANFIRE Study ', Radiology, pp. 152835 . https://doi.org/10.1148/radiol.2016152835
Radiology. Radiological Society of North America Inc.
Radiology, 282(2), 585-597. Radiological Society of North America Inc.
Radiology. Radiological Society of North America Inc.
Radiology, 282(2), 585-597. Radiological Society of North America Inc.
Purpose To (a) investigate the safety of percutaneous irreversible electroporation (IRE) for locally advanced pancreatic cancer and (b) evaluate the quality of life (QOL), pain perception, and efficacy in terms of time to local progression, event-fre
Autor:
Susan Gibbs, Sander W. Spiekstra, Christianne M. A. Reijnders, Lenie J. van den Broek, Ester M. Weijers, Lijc Lambert Bergers, Tanja D. de Gruijl
Publikováno v:
Drug Discovery Today, 21(9), 1479-1488. Elsevier Limited
Bergers, L I J C, Reijnders, C M A, van den Broek, L J, Spiekstra, S W, de Gruijl, T D, Weijers, E M & Gibbs, S 2016, ' Immune-competent human skin disease models ', Drug Discovery Today, vol. 21, no. 9, pp. 1479-1488 . https://doi.org/10.1016/j.drudis.2016.05.008
Drug discovery today, 21(9), 1479-1488. Elsevier
Bergers, L I J C, Reijnders, C M A, van den Broek, L J, Spiekstra, S W, de Gruijl, T D, Weijers, E M & Gibbs, S 2016, ' Immune-competent human skin disease models ', Drug Discovery Today, vol. 21, no. 9, pp. 1479-1488 . https://doi.org/10.1016/j.drudis.2016.05.008
Drug discovery today, 21(9), 1479-1488. Elsevier
All skin diseases have an underlying immune component. Owing to differences in animal and human immunology, the majority of drugs fail in the preclinical or clinical testing phases. Therefore animal alternative methods that incorporate human immunolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bae98f24adb431368edac9b58bc9f258
https://research.vumc.nl/en/publications/673e0047-67a9-46f3-b496-5cc0234349f2
https://research.vumc.nl/en/publications/673e0047-67a9-46f3-b496-5cc0234349f2